| Literature DB >> 25375841 |
Song Ding1, Longwei Xu1, Fan Yang1, Lingcong Kong1, Yichao Zhao1, Lingchen Gao1, Wei Wang1, Rende Xu1, Heng Ge1, Meng Jiang1, Jun Pu1, Ben He1.
Abstract
BACKGROUND AND OBJECTIVES: The predictive value of plaque characteristics assessed by virtual histology-intravascular ultrasound (VH-IVUS) including fibrous tissue (FT), fibrofatty (FF), necrotic core (NC) and dense calcium (DC) in identifying distal embolization after percutaneous coronary intervention (PCI) is still controversial. We performed a systematic review and meta-analysis to summarize the association of pre-PCI plaque composition and post-PCI distal embolization in acute coronary syndrome patients.Entities:
Mesh:
Year: 2014 PMID: 25375841 PMCID: PMC4222782 DOI: 10.1371/journal.pone.0106583
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Process of study selection.
Basical characteristics of studies included in meta-analysis (Normal flow vs. distal embolization).
| Study | Study interval | Location | Sample size (n) | Design | Clinical scenario | PAT | Definition of distal embolization |
| Bae 2008 | NR | Daejeon, South Korea | 45/12 | RSC | AMI | Yes | TIMI flow grade ≤2 |
| Higashikuni 2008 | 2005.6–2006.4 | Tokyo, Japan | 40/9 | RSC | ACS (AMI and UA) | Yes | Decrease of at least 1 grade in TIMI |
| Hong 2009 | NR | Washington DC, United States | 42/38 | RSC | UA | No | cTnI elevation >3X the ULN |
| Hong 2011 | 2006.2–2008.1 | Gwangju, South Korea | 166/24 | RSC | ACS (STEMI, NSTEMI and UA) | No | TIMI flow grade ≤2 |
| Kawaguchi 2007 | 2005.8–2006.12 | Gunma, Japan | 60/11 | PSC | AMI (STEMI) | Yes | ST-segment re-elevation |
| Nakamura 2007 | 2006.1–2006.3 | Saitama, Japan | 42/8 | PSC | AMI (STEMI) | Yes | Decrease in TIMI flow grade |
| Ohshima 2009 | 2007.1–2007.12 | Ehime, Japan | 24/20 | PSC | AMI (STEMI) | Yes | TIMI flow grade ≤2 |
| Ohshima 2011 | NR | Ehime, Japan | 19/34 | RSC | AMI (STEMI) | Yes | TIMI flow grade ≤2 |
| Shin 2011 | NR | Ulsan, South Korea | 90/22 | RSC | UA | No | CK-MB elevation >1X the ULN |
| Zhao 2013 | 2010.9–2011.11 | Zhengzhou, China | 145/21 | RSC | UA | Yes | TIMI flow grade ≤2 |
ACS, acute coronary injury; AMI, acute myocardial infarction; NR, not reported; NSTEMI, non ST-segment elevation myocardial infarction; PAT, percutaneous aspiration thrombectomy; PSC, prospective single center; RSC, retrospective single center; STEMI, ST-segment elevation myocardial infarction; ULN, upper limit of normal.
Clinical characteristics of studies included in meta-analysis (Normal flow vs. distal embolization).
| Study | Mean age (years) | Males (%) | Comorbidities | Pre-PCI use of Aspirin (%) | Use of Statins | Use of GP IIb/IIIa inhibitor | Use of Statins | Use of distal protectiondevices | ||
| HT (%) | DM (%) | HL (%) | ||||||||
| Bae 2008 | 56.2/67.5 | 82.2/66.7 | 40.0/33.3 | 13.3/33.3 | 31.1/25.0 | 100/100 | NR | 0/0 | NR | No |
| Higashikuni 2008 | 66.6/60.6 | 92.5/77.8 | 70.0/55.6 | 30.0/55.6 | 65.0/8 | 30.0/44.4 | 22.5/22.2 | 0/0 | 22.5/22.2 | No |
| Hong 2009 | 65/63 | 47.6/76.3 | 64.3/73.7 | 23.8/31.6 | NR | 92.9/86.8 | NR | 14.3/10.5 | NR | No |
| Hong 2011 | 60.5/60.1 | 65.7/58.3 | 52.4/70.8 | 19.3/25 | NR | NR | NR | 23.5/29.2 | NR | NR |
| Kawaguchi 2007 | NR | NR | 68.3/81.8 | 41.7/9.1 | 45.0/81.8 | NR | NR | 0/0 | NR | No |
| Nakamura 2007 | 65.3/58.5 | 85.7/87.5 | 42.9/25.0 | 23.8/37.5 | 61.9/62.5 | 100/100 | NR | 0/0 | NR | No |
| Ohshima 2009 | 66.0/74.0 | 83.3/65.0 | 58.3/75.0 | 54.2/60.0 | 62.5/45.0 | 100/100 | NR | NR | NR | No |
| Ohshima 2011 | 73/67 | 68.4/85.3 | 78.9/70.6 | 26.3/38.2 | 47.4/61.8 | 100/100 | NR | NR | NR | No |
| Shin 2011 | 61.4/65.5 | 61.1/50.0 | 51.1/72.7 | 32.2/22.7 | 53.3/63.6 | 100/100 | 21.1/27.3 | 0/0 | 21.1/27.3 | No |
| Zhao 2013 | 51/49 | 66.2/66.6 | 59.3/61.9 | 26.9/47.6 | NR | 100/100 | 98.6/95.2 | NR | 98.6/95.2 | No |
DM, diabetes mellitus; HT, hypertension; HL, hyperlipidaemia; NR, not reported;
Figure 2Funnel plot for necrotic core volume outcome data of involved studies.
Newcastle-Ottawa Scale of bias risk for the involved studies.
| Study | Adequacy of selection | Comparability | Outcomes assessment | ||||
| Representativeness of the exposed cohort | Selection of the non-exposed cohort | Ascertainment of exposure | Assessment of Outcomes | Follow-up period long enough for outcome to occur | Adequacy of follow-up period among cohorts | ||
| Bae 2008 | ** | ** | *** | *** | ** | ** | ** |
| Higashikuni 2008 | ** | ** | *** | *** | *** | ** | ** |
| Hong 2009 | ** | ** | ** | *** | ** | ** | ** |
| Hong 2011 | ** | ** | *** | *** | ** | ** | ** |
| Kawaguchi 2007 | ** | ** | ** | ** | ** | ** | ** |
| Nakamura 2007 | ** | ** | *** | *** | *** | ** | ** |
| Ohshima 2009 | ** | ** | *** | *** | ** | ** | ** |
| Ohshima 2011 | ** | ** | *** | *** | *** | ** | ** |
| Shin 2011 | ** | ** | ** | ** | *** | ** | ** |
| Zhao 2013 | ** | ** | *** | ** | ** | ** | ** |
Asterisks are the star rating as per the Newcastle-Ottawa Scale; ** and *** indicate highest rating for these categories.
Composition of plaque by VH-IVUS.
| Study | Absolute volume (mm3) | Percentage (%) | |||||||
| FT | FF | DC | NC | FT | FF | DC | NC | ||
| Bae 2008 | Reflow | 83.8 (66.8) | 18.0 (18.6) | 12.7 (13.9) | 28.8 (26.0) | NR | NR | NR | NR |
| No reflow | 119.6 (61.7) | 36.7 (25.5) | 9.3 (8.9) | 26.1 (21.0) | NR | NR | NR | NR | |
| Higashikuni 2008 | Reflow | NR | NR | NR | NR | 68.3 (10.2) | 15.5 (7.1) | 4.8 (3.6) | 11.7 (7.9) |
| No reflow | NR | NR | NR | NR | 59.6 (11.2) | 12.0 (9.7) | 4.7 (3.3) | 22.1 (9.3) | |
| Hong 2009 | Reflow | 33.9(14.2) | 16.9(11.6) | 3.2(3.0) | 7.9(4.4) | 55.0(11.6) | 27.5(13.0) | 4.8(3.4) | 12.8(8.4) |
| No reflow | 38.4(19.0) | 13.1(9.9) | 3.8(3.0) | 13.6(6.4) | 55.7(13.1) | 19.0(9.3) | 5.5(3.9) | 19.8(10.4) | |
| Hong 2011 | Reflow | 77 (75.4) | 20 (25.4) | 10 (11.5) | 16 (16.9) | 61 (9.9) | 16 (9.9) | 9 (6.8) | 14 (8.0) |
| No reflow | 76 (50.0) | 15 (18.5) | 19 (20.0) | 30 (23.8) | 55 (14.0) | 9 (6.1) | 14 (8.0) | 22 (11.0) | |
| Kawaguchi 2007 | Reflow | 68.2 (35.3) | 13.2 (11.4) | 9.6 (13.9) | 20.4 (19.2) | NR | NR | NR | NR |
| No reflow | 67.1 (30.7) | 9.8 (10.4) | 12.2 (8.6) | 32.9 (14.1) | NR | NR | NR | NR | |
| Nakamura 2007 | Reflow | NR | NR | NR | NR | 67.0 (1.5) | 17.0 (1.1) | 4.8 (0.6) | 11.2 (1.2) |
| No reflow | NR | NR | NR | NR | 68.3 (2.1) | 23.1 (3.5) | 2.6 (0.6) | 6.3 (1.0) | |
| Ohshima 2009 | Reflow | 56.6 (21.8) | 8.6 (5.2) | 6.5 (5.3) | 12.0 (7.4) | 67.8 (10.2) | 10.1 (3.9) | 7.8 (5.2) | 14.3 (6.7) |
| No reflow | 56.2 (32.6) | 14.2 (11.4) | 10.3 (7.6) | 14.1 (6.7) | 57.5 (10.7) | 14.5 (9.6) | 11.8 (8.9) | 15.8 (7.4) | |
| Ohshima 2011 | Reflow | 57.0 (33.3) | 14.7 (11.5) | 9.3 (6.0) | 13.7 (6.7) | 57.5 (11.0) | 14.8 (9.7) | 11.3 (9.0) | 15.8 (7.6) |
| No reflow | 67.5 (29.7) | 15.0 (11.7) | 11.0 (8.8) | 16.8 (10.0) | 61.2 (10.8) | 13.4 (8.1) | 10.2 (7.2) | 15.3 (6.0) | |
| Shin 2011 | Reflow | NR | NR | 3.9 (3.7) | 8.8 (5.8) | NR | NR | NR | NR |
| No reflow | NR | NR | 9.1 (5.8) | 17.2 (8.8) | NR | NR | NR | NR | |
| Zhao 2013 | Reflow | NR | NR | NR | NR | 59.24 (6.72) | 17.90 (3.21) | 8.36 (3.13) | 14.50 (5.48) |
| No reflow | NR | NR | NR | NR | 50.26 (8.72) | 15.29 (2.83) | 9.53 (2.99) | 24.92 (10.04) | |
Data are presented as mean (SD)
FT, fibrous tissue; FF, fibrofatty; NC, necrotic core; DC, dense calcium.
Figure 3Absolute volume comparison of four different plaque compositions through the entire culprit lesion between the normal flow group and the distal embolization group.
(A) Absolute fibrous volume comparison; (B) Absolute fibrofatty volume comparison; (C) Absolute dense calcium volume comparison; (D) Absolute necrotic core volume comparison;
Figure 4Percentage comparison of four different plaque compositions through the entire culprit lesion between the normal flow group and the distal embolization group.
(A) Fibrous percentage comparison; (B) Fibrofatty percentage comparison; (C) Dense calcium percentage comparison; (D) Necrotic core percentage comparison.
Subgroup analyses of the association of the absolute volume of plaque components with the onset of distal embolization.
| FT | FF | DC | NC | |||||
| Subgroup | WMD (95% CI, mm3) |
| WMD (95% CI, mm3) |
| WMD (95% CI, mm3) |
| WMD (95% CI, mm3) |
|
|
| ||||||||
| AMI | 5.21 (−4.93, 15.35) | 0.31 | 3.17 (−3.25, 9.59) | 0.33 | 1.81 (−0.81, 4.44) | 0.18 | 3.56 (−0.37, 7.50) | 0.08 |
| Unstable angina | 4.50 (−2.91, 11.91) | 0.23 | −3.80 (−8.51, 0.91) | 0.11 | 2.77 (−1.73, 7.27) | 0.23 | 6.61 (4.11, 9.12) | <0.001 |
|
| ||||||||
| Angiographic evidence | 5.62 (−4.83, 16.07) | 0.29 | 3.11 (−3.77, 10.00) | 0.38 | 2.44 (−1.34, 6.22) | 0.21 | 3.88 (−0.62, 8.38) | 0.09 |
| Clinical relevancy | 3.84 (−3.12, 10.80) | 0.28 | −3.67 (−7.54, 0.20) | 0.06 | 2.71 (−0.88, 6.29) | 0.14 | 7.13 (4.40, 9.87) | <0.001 |
|
| ||||||||
| With thrombectomy | −4.36 (−10.42, 1.71) | 0.16 | 0.80 (−3.89, 5.49) | 0.74 | 0.06 (−2.17, 2.30) | 0.96 | 3.56 (−0.37, 7.50) | 0.08 |
| Without thrombectomy | −2.57 (−9.14, 3.99) | 0.44 | −7.38 (−9.86, −4.90) | <0.001 | 2.59 (−1.60, 6.77) | 0.23 | 7.47 (4.25, 10.69) | <0.001 |
FT, fibrous tissue; FF, fibrofatty; NC, necrotic core; DC, dense calcium; WMD, weighted mean differences; AMI, acute myocardial infarction.
Subgroup analyses of the association of the percentage of plaque components with the onset of distal embolization.
| FT | FF | DC | NC | |||||
| Subgroup | WMD (95% CI, %) |
| WMD (95% CI, %) |
| WMD (95% CI, %) |
| WMD (95% CI, %) |
|
|
| ||||||||
| AMI | −1.48 (−8.40, 5.44) | 0.68 | 3.49 (−0.68, 7.66) | 0.10 | −0.18 (−3.89, 3.53) | 0.92 | −1.67 (−6.04, 2.70) | 0.45 |
| Unstable angina | −4.34 (−13.81, 5.14) | 0.37 | −5.06 (−10.75, 0.63) | 0.08 | 0.97 (−0.07, 2.02) | 0.07 | 8.64 (5.29, 11.99) | <0.001 |
|
| ||||||||
| Angiographic evidence | −4.60 (−9.87, 0.67) | 0.09 | −0.61 (−4.91, 3.70) | 0.78 | 0.87 (−1.49, 3.24) | 0.47 | 3.91 (−2.30, 10.11) | 0.22 |
| Clinical relevancy | 0.70 (−4.75, 6.15) | 0.80 | −8.50 (−13.42, −3.58) | <0.001 | 0.70 (−0.91, 2.31) | 0.39 | 7.00 (2.83,11.17) | 0.001 |
|
| ||||||||
| With thrombectomy | 5.21 (−4.93, 15.35) | 0.31 | 3.17 (−3.25, 9.59) | 0.33 | 1.81 (−0.81, 4.44) | 0.18 | 3.07 (−3.45,9.59) | 0.36 |
| Without thrombectomy | 3.98 (−3.07, 11.04) | 0.27 | −4.09 (−8.19, 0.01) | 0.05 | 3.85 (−0.46, 8.17) | 0.08 | 7.45 (4.38, 10.53) | <0.001 |
FT, fibrous tissue; FF, fibrofatty; NC, necrotic core; DC, dense calcium; WMD, weighted mean differences; AMI, acute myocardial infarction.